Therapeutic drug monitoring of voriconazole and posaconazole (Q37833074)

24 August 2017

1 reference

title

Therapeutic drug monitoring of voriconazole and posaconazole (English)

1 reference

24 August 2017

1 reference

Trana Hussaini

1

0 references

Oliver A Cornely

object named as

Oliver A Cornely

series ordinal

5

0 references

Jörg Janne Vehreschild

series ordinal

4

object named as

Janne J Vehreschild

1 reference

24 August 2017

2

Maria J G T Rüping

1 reference

24 August 2017

3

Fedja Farowski

1 reference

PubMed ID

21275497

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

31

1 reference

24 August 2017

2

1 reference

24 August 2017

214-225

1 reference

Update on the epidemiology and diagnosis of invasive fungal infection.

24 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Factors associated with overall and attributable mortality in invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Voriconazole concentrations and outcome of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Hallucinations during voriconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

Intracellular concentrations of posaconazole in different compartments of peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.214

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.2.214

1 reference

24 August 2017

1 reference

PubMed ID

21275497